Rethinking neurodegeneration through blood-based biomarkers

Wednesday, October 8, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT

Proteomics is redefining how we predict, diagnose, and develop treatments for neurodegenerative diseases. Join this roundtable discussion with two leading experts in neurology as they explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets with the SomaScan™ Assay:

• Tony Wyss-Coray, PhD (Stanford University School of Medicine) will discuss how combining protein measurements in blood and cerebrospinal fluid with genetic data has revealed valuable insights into brain aging.
• Jacob Vogel, PhD (Lund University) will present discoveries from the Global Neurodegeneration Proteomics Consortium (GNPC), revealing protein signatures that predict dementia, identify multiple pathologies, and track changes in protein networks over time.

This roundtable discussion will be moderated by Steve Williams, MD, PhD (Chief Medical Officer, Standard BioTools).

Secure your spot today to hear what the next decade of neurological research could look like.

Key learning objectives:

• Blood vs. brain biomarkers: Can plasma replace or complement CSF?
• Early detection: How can protein patterns predict dementia before symptoms appear?
• Data scale: Is bigger always better, or is deeper profiling the key?

Who should attend?

Translational and clinical researchers studying neurology and aging across all research sectors (e.g., academia, biotech, government, biopharma).

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.